Profusa, Inc. · NASDAQ:PFSA
Profusa — Investor Presentation (October 2025)
22 slides from Profusa's investor presentation, Oct 21, 2025
Slide 1: Investor Presentation October 2025
NASDAQ: PFSA October 2025 INVESTOR PRESENTATION ”Pioneering real time biochemistry that drives AI - led, personalized healthcare technologies”
Slide 2: Disclaimer and Safe Harbor Statement
NASDAQ: PFSA DISCLAIMER AND SAFE HARBOR STATEMENT 2 Disclaimer This presentation (“Presentation”) is being issued by Profusa, Inc. (the “Company” or “Profusa”) for information purposes onl y. The content of this Presentation has not been approved by any securities regulatory authority. Reliance on t
Slide 3: Key Investment Highlights
NASDAQ: PFSA 3 KEY INVESTMENT HIGHLIGHTS • Platform technology yields multiple commercial revenue opportunities in the US and Europe • >$10.5B+ global TAM in tissue and pulse oximetry oxygen monitoring by 2030 (1) • 500M+ people globally with diabetes in 2024, growing 45% by 2050 (2) • Commercial st
Slide 4: Profusa Platform Technology
NASDAQ: PFSA PROFUSA PLATFORM TECHNOLOGY 4 Profusa Cloud Low maintenance, cost effective, AI adaptive personal health management platform Low - cost novel subcontainous biologically compatible hydrogel micro - sensor 9+ months functionality INJECTABLE HYDROGEL MICRO - SENSOR REUSABLE OPTICAL READER
Slide 5: Artificial Intelligence (AI) Driven Digital Healthcare
NASDAQ: PFSA 5 ARTIFICAL INTELLIGENCE (AI) DRIVEN DIGITAL HEALTHCARE • Machine learning to create algorithms for enhanced monitoring • Accounting for variations of the tissue composition for continuous accuracy while still using the single injectable sensor • Multiple calculations around other physi
Slide 6: Operational Focus to Drive Revenue
NASDAQ: PFSA Revenue/ Commercial AI and Data Science Finance/ Resources Regulatory/ Clinical Manufacture/ Operations OPERATIONAL FOCUS TO DRIVE REVENUE 6 Q1 ‘26 Revenue; Projected $200 - 250 million by 2030 • 3 collaborations with high volume centers in key EU markets with additions planned • Distri
Slide 7: Revenue Platform by Clinical Indication
NASDAQ: PFSA REVENUE PLATFORM BY CLINICAL INDICATION 7 OXYGEN PLATFORM: GLUCOSE PLATFORM: DATA DISCOVERY: • Planned 1Q2026 Critical Limb Ischemia (CLI) launch in EU • Planned 1Q2027E CLI launch in US • Wound care applications • Home remote monitoring potential • Other potential applications: cell hy
Slide 8: Mission Driven Executive Management
NASDAQ: PFSA MISSION DRIVEN EXECUTIVE MANAGEMENT 8 Ben Hwang Ph.D., Chairman, CEO From his early exposure as an undergraduate research fellow at the lab of Leroy Hood at Caltech, where the automated DNA sequencer was developed, to bringing cutting edge life sciences tools to the market at Life Techn
Slide 9: Tissue Oxygen Monitoring
9 Tissue Oxygen Monitoring NASDAQ: PFSA Computer generated Lumee App image
Slide 10: Tissue Oxygen Market Opportunity
NASDAQ: PFSA TISSUE OXYGEN MARKET OPPORTUNITY 10 LARGE UNMET NEED • ~6.5 million patients with Critical Limb Ischemia (CLI) in US, Europe, and Japan (1) • ~$4.9 billion market in 2022 growing at 8% CAGR (3) • ~1.1 million CLI procedures in US and EU in 2025 (1)(2)(3) • Lack of decision support: ⎼ De
Slide 11: Lumee Oxygen in Action with CLI Patient
NASDAQ: PFSA LUMEE OXYGEN IN ACTION WITH CLI PATIENT FIRST OXYGEN APPLICATION REVENUE EXPECTED1Q2026 11 Therapeutic Interventions Lumee Oxygen Index [ - ] Remove Sheath Baseline Note (1) J. Vasc . Surg., June 2015, Volume 61:6, 1501 - 10 Lumee Oxygen Platform reports local tissue oxygen levels durin
Slide 12: Continuous Glucose Monitoring
12 Continuous Glucose Monitoring NASDAQ: PFSA Computer generated Lumee App image
Slide 13: >590M Diabetes Patients Globally – CGM Opportunity
NASDAQ: PFSA >590M DIABETES PATIENTS GLOBALLY – CGM OPPORTUNITY FROM “CAN YOU AFFORD IT” TO “DO YOU NEED IT?” 13 Current CGM TAM Profusa TAM • Established benefit of CGM across diabetes spectrum • Woefully under - penetrated opportunity >2M CGM users ~300M Diagnosed ~30M Diagnosed (US/EU) prediabete
Slide 14: Differentiated, Advanced CGM Solution
NASDAQ: PFSA DIFFERENTIATED, ADVANCED CGM SOLUTION 14 Insertion apparatus Insertion apparatus Surgical insertion and removal Simple injection – hypodermic needle Sensor Functional Lifetime (days) Deployment Method Dexcom Medtronic Abbott Senseonics Source: https://www.dexcom.com/en - us/faqs/can - i
Slide 15: Data Rich, Accessible, Low-Cost CGM for All
NASDAQ: PFSA DATA RICH, ACCESSIBLE, LOW - COST CGM FOR ALL 15 Profusa Cloud Reader Profusa’s CGM Solution Current CGM Pain Points x Overcomes foreign body response: > 270 days functionality New sensor required every 10 – 14 days x Simple hypodermic needle injection of sensor 180 - day solution r
Slide 16: Lumee Glucose Clinical Trial
NASDAQ: PFSA 16 LUMEE GLUCOSE CLINICAL TRIAL Demonstrated Safety and Functionality • Clinical trial evaluated the safety and functionality of the glucose platform, sensor, reader and AI platform ⎼ 4 Clinical sites ⎼ Two European clinical sites ⎼ Two Asian clinical sites • 54 Subjects enrolled • 108
Slide 17: Commercialization Roadmap
NASDAQ: PFSA COMMERCIALIZATION ROADMAP 17 2027E 2026E 2025E Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Program Research Use Only and Government Contract Revenues Research & Government Lumee TM Oxygen Lumee TM Glucose EU Commercialization and Revenues US Oxygen Revenues FDA Submission Process US Pivotal Study Hum
Slide 18: EU Oxygen Roadmap to Revenue
NASDAQ: PFSA EU OXYGEN ROADMAP TO REVENUE Manufacturing and Supply Chain 18 2025 Aug Sep Oct Nov Dec 2026 Jan Feb Mar Apr May Jun Jul Aug Sep Update EU CE Mark (MDR) Milestones • Technical file submission – Nov 2025 • Commence compliance testing – Dec 2025 • Approval – Apr 2026 Sensor & Pen Producti
Slide 19: Oxygen Platform Revenue Operating Model
NASDAQ: PFSA OXYGEN PLATFORM REVENUE OPERATING MODEL 19 Distribution partners and Profusa commercial team will market directly to Centers • High Volume Hospital Centers: perform 1,000 to1,500 procedures/year • Ambulatory Centers & Doctors’ Offices: perform 200 – 1,000 procedures/year Equipment requi
Slide 20: Oxygen Commercialization Paves Way for Glucose
NASDAQ: PFSA OXYGEN COMMERCIALIZATION PAVES WAY FOR GLUCOSE 20 2026 2027 2028 2029 2030 EU O2 US 02 Glucose Projected Revenue ($millions) Assumptions Critical Limb Ischemia (CLI) est. 2025 Market: ~1.1 million procedures in the US and EU, growing at 8% CAGR (1)(2)(3) • 2025 est. procedures in EU: ~7
Slide 21: Platform Value Proposition
NASDAQ: PFSA PLATFORM VALUE PROPOSITION 21 DIFFERENTIATED TECHNOLOGY • Potential to change industry standard functionality from 14 to 90 days for initial product and eventually >270 days • ~10 years and ~$100M invested in developing technology. More than 85 global patents issued and pending • Clinic
Slide 22: Investor & Media Relations
22 Investor & Media Relations: CORE IR email: info@coreir.com phone: 1 (212) 655 - 0924 NASDAQ: PFSA